Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bayer HealthCare has received the US Food and Drug Administration approval to proceed with its expanded access program for the investigational drug radium-223 chloride.
Subscribe to our email newsletter
Expanded access refers to the use of an investigational drug, under certain circumstances, to treat patients with a serious disease or condition who cannot participate in a controlled clinical trial.
Radium-223 chloride is the investigational drug developed for patients diagnosed with castration-resistant prostate cancer (CRPC)/hormone-refractory prostate cancer (HRPC) with symptomatic bone metastases.
Radium-223 chloride will be made available to patients through qualified clinical sites participating in this program, the company said.